PRSS23 promotes ovarian cancer peritoneal dissemination independent of protease activity

Ovarian cancer metastasizes via peritoneal dissemination, requiring tumor cells to resist detachment-induced cell death (anoikis) in suspension and to reinitiate proliferation after seeding. Because disseminating ovarian cancer cells persist in malignant ascites enriched in extracellular S1 family serine proteases, we surveyed S1 protease gene expression across ovarian cancer cohorts to identify those most associated with poor outcomes. High expression of multiple family members was associated with poor survival, with HTRA3, TMPRSS12, and PRSS23 among the strongest hits. TMPRSS12 transcripts were below the limit of detection in our cell line panel, while HTRA3 depletion showed modest, histotype-dependent effects. In contrast, PRSS23 knockdown reduced proliferation and increased anoikis sensitivity in high-grade serous (HGSOC) and clear cell (OCCC) ovarian carcinoma cell lines, and diminished tumor establishment, dissemination, and ascites in intraperitoneal xenograft models. RNA-seq of PRSS23-depleted cells revealed a conserved program of reduced cell-cycle/DNA repair gene expression with induction of inflammatory and adhesion/epithelial-mesenchymal transition pathways. Endogenous epitope tagging demonstrated that PRSS23 is synthesized as a precursor and secreted as a processed, glycosylated protease homology domain that retains the catalytic triad, yet lacks the canonical Ile16-Asp194 zymogen activation switch. In complementary biochemical assays, PRSS23 showed no detectable serine hydrolase activity in either activity-based probe labeling of conditioned media or chromogenic peptide substrate assays using the recombinant protease domain. Furthermore, pro-tumorigenic phenotypes persisted after mutation of the putative catalytic serine. Together, these findings demonstrate protease-independent PRSS23 function in ovarian cancer peritoneal dissemination, and suggest that PRSS23 may ultimately warrant reclassification as a serine pseudoprotease.

Authors

Institutions

Publication Details

Journal
Journal of Biological Chemistry
Published
2026-04-14
DOI
https://doi.org/10.1016/j.jbc.2026.111450
Primary Topic
Protease and Inhibitor Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PRSS23 promotes ovarian cancer peritoneal dissemination independent of protease activity

Erin MIller, Christine Mehner, Niv Papo, Derek C. Radisky et al.
Journal of Biological Chemistry
Protease and Inhibitor Mechanisms
article

PRSS23 promotes ovarian cancer peritoneal dissemination independent of protease activity

Erin MIller, Christine Mehner, Niv Papo, Derek C. Radisky, Alexandra Hockla, Sharoon Akhtar, Stefan Ilić, Evette S. Radisky, Eran Maina, Matt Coban
article en

Abstract

Ovarian cancer metastasizes via peritoneal dissemination, requiring tumor cells to resist detachment-induced cell death (anoikis) in suspension and to reinitiate proliferation after seeding. Because disseminating ovarian cancer cells persist in malignant ascites enriched in extracellular S1 family serine proteases, we surveyed S1 protease gene expression across ovarian cancer cohorts to identify those most associated with poor outcomes. High expression of multiple family members was associated with poor survival, with HTRA3, TMPRSS12, and PRSS23 among the strongest hits. TMPRSS12 transcripts were below the limit of detection in our cell line panel, while HTRA3 depletion showed modest, histotype-dependent effects. In contrast, PRSS23 knockdown reduced proliferation and increased anoikis sensitivity in high-grade serous (HGSOC) and clear cell (OCCC) ovarian carcinoma cell lines, and diminished tumor establishment, dissemination, and ascites in intraperitoneal xenograft models. RNA-seq of PRSS23-depleted cells revealed a conserved program of reduced cell-cycle/DNA repair gene expression with induction of inflammatory and adhesion/epithelial-mesenchymal transition pathways. Endogenous epitope tagging demonstrated that PRSS23 is synthesized as a precursor and secreted as a processed, glycosylated protease homology domain that retains the catalytic triad, yet lacks the canonical Ile16-Asp194 zymogen activation switch. In complementary biochemical assays, PRSS23 showed no detectable serine hydrolase activity in either activity-based probe labeling of conditioned media or chromogenic peptide substrate assays using the recombinant protease domain. Furthermore, pro-tumorigenic phenotypes persisted after mutation of the putative catalytic serine. Together, these findings demonstrate protease-independent PRSS23 function in ovarian cancer peritoneal dissemination, and suggest that PRSS23 may ultimately warrant reclassification as a serine pseudoprotease.

Journal of Biological ChemistryVol. 302(6)
Ben-Gurion University of the Negev (IL), Jacksonville College (US), Mayo Clinic in Florida (US)
United States-Israel Binational Science Foundation
Zero hunger
Openalex Percentile: Top 25%
Protease and Inhibitor Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.